RXi Pharmaceuticals Corporation (NASDAQ:RXII) insider Alexey Eliseev sold 23,200 shares of the stock in a transaction on Friday, September 1st. The shares were sold at an average price of $0.57, for a total transaction of $13,224.00. Following the completion of the transaction, the insider now owns 1,127,112 shares of the company’s stock, valued at approximately $642,453.84. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Shares of RXi Pharmaceuticals Corporation (NASDAQ RXII) traded down 1.75% during trading on Friday, hitting $0.56. 72,462 shares of the stock were exchanged. RXi Pharmaceuticals Corporation has a 1-year low of $0.51 and a 1-year high of $2.93. The company’s market cap is $13.02 million. The firm’s 50-day moving average is $0.60 and its 200 day moving average is $0.65.

RXi Pharmaceuticals Corporation (NASDAQ:RXII) last posted its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.11) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.11). During the same quarter in the prior year, the firm posted ($0.34) EPS. Equities analysts forecast that RXi Pharmaceuticals Corporation will post ($1.77) earnings per share for the current fiscal year.

WARNING: This report was reported by Daily Political and is the property of of Daily Political. If you are accessing this report on another publication, it was illegally copied and republished in violation of international trademark & copyright laws. The original version of this report can be viewed at https://www.dailypolitical.com/2017/09/02/rxi-pharmaceuticals-corporation-rxii-insider-alexey-eliseev-sells-23200-shares.html.

An institutional investor recently raised its position in RXi Pharmaceuticals Corporation stock. Renaissance Technologies LLC raised its stake in RXi Pharmaceuticals Corporation (NASDAQ:RXII) by 26.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 229,980 shares of the biotechnology company’s stock after buying an additional 48,200 shares during the period. Renaissance Technologies LLC owned about 3.49% of RXi Pharmaceuticals Corporation worth $164,000 as of its most recent SEC filing. 1.70% of the stock is currently owned by institutional investors.

RXi Pharmaceuticals Corporation Company Profile

RXi Pharmaceuticals Corporation is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. The Company’s development programs are based on its self-delivering RNAi (sd-rxRNA) platform and Samcyprone, a topical immunomodulator.

Insider Buying and Selling by Quarter for RXi Pharmaceuticals Corporation (NASDAQ:RXII)

Receive News & Ratings for RXi Pharmaceuticals Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RXi Pharmaceuticals Corporation and related companies with MarketBeat.com's FREE daily email newsletter.